Institut Pasteur is the premier non-profit foundation that was founded in 1887 and has since originated 10 Nobel Prizes.
Launched in 2011, BioSpeedia develop and manufacture French test kits for rapid screening and diagnosis of Covid-19, to protect and allow your community to function and create a safe environment to reopen and keep it open.
BioSpeedia also signed a strategic and Technologic Partnership with SICPA to offer a service layer to allow secured traveling in addition to our screening product line.
An Industrial Partnership has been signed as well with Delpharm, who manufacture in France our rapid test. We will have soon the first and only French fully automated production line for “lateral flow” testing.
BioSpeedia worldwide sales and distribution, product registration, liaising with regulatory authorities, logistics and shipping is handled by our distribution arm, BioVitess Ltd. a UK based sister company.
- Founded in 2011
The establishment of BioSpeedia
After spending 3 decades at Institut Pasteur, Yves Germani and Evelyne Begaud, establish the Company as the official spin-off from the premier French Institute.
Grant from Aide au Partenariat Technologique
Developed fast and accurate lateral flow diagnostic kit to detect Neisseria meningitidis (Menincococcus)
Developed a diagnostic kit to rapidly detect bacterial meningitis using spinal fluid and subsequently using urine samples.
WHO approves MeningoSpeed detection kit in spinal fluid
Received CE Mark for our SARS-CoV-2 rapid antibody test kit
COVID19SEROSpeed-IgM-IgG Test is an immunochromatographic assay designed for the qualitative detection and differentiation of specific IgM and IgG antibodies to coronavirus 2019-nCoV or SARS-CoV-2 in human fingertip blood samples
Seal of Excellence from H2020
For COVID-19 Response
Received CE Mark for our SARS-CoV-2 rapid antigen test kit
COVID-19SPEEDAntigen Test is a colloidal gold enhanced double antibody sandwich immunoassay for qualitative determination of SARS-CoV-2 antigen in human nasal swabs.